Stock comparison
AbbVie
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABBV
AbbVie
Market cap
$384.1B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.47B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABBV | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 57C | 65C | GMAB |
| Benjamin Graham | 88A | 64C | ABBV |
| Philip Fisher | 58C | 48D | ABBV |
| Peter Lynch | 30F | 25F | ABBV |
| Joel Greenblatt | 41D | 76B | GMAB |
| Charlie Munger | 64D | 68C | GMAB |
| Terry Smith | 56D | 71C | GMAB |
Side-by-side metrics
| Metric | ABBV | GMAB |
|---|---|---|
| Market cap | $384.1B | $16.47B |
| P/E (TTM) | 103.6x | 6.2x |
| EV/EBIT | 21.8x | 12.0x |
| ROIC (TTM) | 10.29% | 43.78% |
| Gross margin | 73.46% | 93.88% |
| Net margin | 5.79% | 18.23% |
| Revenue CAGR 5y | 2.14% | -18.45% |
| EPS CAGR 5y | -22.23% | -23.48% |
| Debt / Equity | 2.6x | 0.1x |
| Dividend yield | 3.17% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABBV leads on
- Revenue CAGR 5y2.14%vs -18.45%+112%
- Dividend yield3.17%vs 0.0%+100%
- Market cap$384.1Bvs $16.47B+96%
- EPS CAGR 5y-22.23%vs -23.48%+5%
GMAB leads on
- Debt / Equity0.1xvs 2.6x+97%
- P/E (TTM)6.2xvs 103.6x+94%
- ROIC (TTM)43.78%vs 10.29%+76%
- Net margin18.23%vs 5.79%+68%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.